Gilead wins OK to promote drug for hepatitis B

LOS ANGELES Tue Aug 12, 2008 4:47am IST

Related Topics

Stocks

   

LOS ANGELES (Reuters) - Gilead Sciences said on Monday it won U.S. approval to promote its AIDS drug Viread for treating adults with chronic hepatitis B.

Hepatitis B is a potentially life-threatening infection that can destroy the liver. Gilead estimates that more than 400 million people worldwide have the disease, which is most prevalent in Asian countries. It is the leading cause of liver cancer and complications kill up to 1.2 million people per year.

Viread, known generically as tenofovir, is a once-daily tablet that works by blocking an enzyme necessary for the virus to replicate in liver cells.

The drug has been available in the United States as a treatment for HIV infection in adults since 2001.

Gilead already markets another hepatitis B drug, Hepsera, which saw second-quarter sales of $90 million.

RBC Capital Markets analyst Jason Kantor estimated that Hepsera currently has 44 percent of the market, which remains significantly underserved.

"Compared to the available drugs, Viread is likely to be considered best-in-class based on its potency, resistance profile, long-term safety, and price," he said in a recent research note.

Truvada, which had second-quarter sales of $516 million, is a pill that combines Viread with Emtriva, another of Gilead's HIV drugs.

Shares of Gilead, which lost 34 cents to close at $56.43 on Nasdaq, were slightly higher at $57.23 in after hours trading. Year-to-date, the stock is up about 24 percent, compared with a gain of about 11 percent for the Biotech Index.

(Reporting by Deena Beasley in Los Angeles and Lisa Richwine in Washington; editing by Carol Bishopric)

FILED UNDER:

Fighting Ebola

Reuters Showcase

GDP Growth

GDP Growth

India's economic growth revised up by almost 50 pct.  Full Article 

Stake Sale

Stake Sale

Strong demand for Coal India boosts privatisation drive.  Full Article 

SpiceJet Bailout

SpiceJet Bailout

SpiceJet board approves up to $243 mln share sale plan  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Romney Opts Out

Romney Opts Out

Republican Romney opts out of 2016 run for president.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Safety Concerns

Safety Concerns

Aviation leaders seek new safety mandate after deadly 2014.  Full Article 

England Beat India

England Beat India

England reach final after Taylor-made victory.  Full Article 

Movie Review: Hawaizaada

Movie Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage